COVID-19 vaccine (BBIBP-CorV)

URI: https://gptkb.org/entity/COVID-19_vaccine_(BBIBP-CorV)
GPTKB entity
Statements (46)
Predicate Object
gptkbp:instanceOf vaccine
gptkbp:adjuvant aluminum hydroxide
gptkbp:age adults 18 years and older
gptkbp:alsoKnownAs gptkb:Sinopharm_BIBP_COVID-19_vaccine
gptkb:BBIBP-CorV
gptkbp:antigen gptkb:SARS-CoV-2_virus
gptkbp:approvedBy gptkb:China
over 90 countries
2020-12-30
gptkbp:boosterDoseRecommended yes
gptkbp:boosterInterval 6 months after second dose
gptkbp:clinicalTrialPhase3Locations gptkb:Argentina
gptkb:Bahrain
gptkb:Egypt
gptkb:Jordan
gptkb:Peru
gptkb:United_Arab_Emirates
gptkbp:countryOfOrigin gptkb:China
gptkbp:developedBy gptkb:Sinopharm
gptkbp:distribution global
gptkbp:dosingRegimen two doses
gptkbp:efficacyAgainstSymptomaticCOVID19 ~79%
gptkbp:emergencyServices gptkb:China
gptkb:World_Health_Organization
many other countries
https://www.w3.org/2000/01/rdf-schema#label COVID-19 vaccine (BBIBP-CorV)
gptkbp:includedInCOVAX yes
gptkbp:includedInWHOList yes
gptkbp:intervalBetweenDoses 3–4 weeks
gptkbp:manufacturer gptkb:Beijing_Institute_of_Biological_Products
gptkbp:partOf Sinopharm COVID-19 vaccines
gptkbp:regulates full approval in some countries
emergency use
gptkbp:routeOfAdministration intramuscular injection
gptkbp:sideEffect fever
fatigue
headache
muscle pain
pain at injection site
gptkbp:storage 2–8°C
gptkbp:target gptkb:COVID-19
gptkbp:technology gptkb:virus
gptkbp:type inactivated whole virus vaccine
gptkbp:WHOEmergencyUseListing 2021-05-07
gptkbp:bfsParent gptkb:Beijing_Institute_of_Biological_Products
gptkbp:bfsLayer 6